{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T09:46:17Z","timestamp":1793094377136,"version":"4.5.0"},"reference-count":14,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.eururo.2026.01.015","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T05:37:06Z","timestamp":1770097026000},"page":"7-12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Updated 5-year Survival Results from PURE-01, a Phase 2 Study of Neoadjuvant Pembrolizumab Followed by Radical Cystectomy in Patients with Muscle-invasive Bladder Cancer"],"prefix":"10.1016","volume":"90","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1199-2338","authenticated-orcid":false,"given":"Valentina","family":"Tateo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Basile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Giannatempo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joep J.","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Proudfoot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigida A.","family":"Maiorano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Cigliola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Mercinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elai","family":"Davicioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Moschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Tremolada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Rota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Brembilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"Colecchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"De Cobelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Montorsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Necchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2026.01.015_b0005","unstructured":"van der Heijden AG, Bruins HM, Carrion A, et al. EAU guidelines on muscle-invasive and metastatic bladder cancer. Arnhem, The Netherlands: European Association of Urology; 2025."},{"key":"10.1016\/j.eururo.2026.01.015_b0010","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.01.015_b0015","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2026.01.015_b0020","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer","volume":"391","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"issue":"Suppl 2","key":"10.1016\/j.eururo.2026.01.015_b0025","first-page":"S1763","article-title":"LBA2\u2003Perioperative (periop) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: the phase III KEYNOTE-905 study","volume":"36","author":"Vulsteke","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2026.01.015_b0030","doi-asserted-by":"crossref","first-page":"3353","DOI":"10.1200\/JCO.18.01148","article-title":"Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): an open-label, single-arm, phase II study","volume":"36","author":"Necchi","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2026.01.015_b0035","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1158\/1078-0432.CCR-22-2158","article-title":"Neoadjuvant pembrolizumab and radical cystectomy in patients with muscle-invasive urothelial bladder cancer: 3-year median follow-up update of PURE-01 trial","volume":"28","author":"Basile","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2026.01.015_b0040","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.eururo.2017.03.030","article-title":"Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy","volume":"72","author":"Seiler","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.01.015_b0045","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.eururo.2020.02.028","article-title":"Impact of molecular subtyping and immune infiltration on pathological response and outcome following neoadjuvant pembrolizumab in muscle-invasive bladder cancer","volume":"77","author":"Necchi","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2026.01.015_b0050","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.cell.2020.10.027","article-title":"Persistent cancer cells: the deadly survivors","volume":"183","author":"Shen","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.eururo.2026.01.015_b0055","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1038\/s41591-023-02568-1","article-title":"Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial","volume":"29","author":"Galsky","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.eururo.2026.01.015_b0060","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1200\/JCO-24-01214","article-title":"Phase II trial of risk-enabled therapy after neoadjuvant chemotherapy for muscle-invasive bladder cancer (RETAIN 1)","volume":"43","author":"Geynisman","year":"2025","journal-title":"J Clin Oncol"},{"issue":"5 Suppl","key":"10.1016\/j.eururo.2026.01.015_b0065","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1200\/JCO.2025.43.5_suppl.815","article-title":"A phase 2 trial of risk enabled therapy after neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer (RETAIN-2)","volume":"43","author":"Ghatalia","year":"2025","journal-title":"J Clin Oncol"},{"issue":"16 Suppl","key":"10.1016\/j.eururo.2026.01.015_b0070","doi-asserted-by":"crossref","first-page":"4518","DOI":"10.1200\/JCO.2025.43.16_suppl.4518","article-title":"First results of SURE-02: a phase 2 study of neoadjuvant sacituzumab govitecan (SG) plus pembrolizumab (Pembro), followed by response-adapted bladder sparing and adjuvant pembro, in patients with muscle-invasive bladder cancer (MIBC)","volume":"43","author":"Necchi","year":"2025","journal-title":"J Clin Oncol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283826000229?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283826000229?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T18:39:42Z","timestamp":1783017582000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283826000229"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0302283826000229"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2026.01.015","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Updated 5-year Survival Results from PURE-01, a Phase 2 Study of Neoadjuvant Pembrolizumab Followed by Radical Cystectomy in Patients with Muscle-invasive Bladder Cancer","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2026.01.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}